CD274 and metastatic melanoma: Due to the lack of published data on anti-PD1/PD-L1 immunotherapy in GC, published IMvigor210 (advanced urothelial cancer cohort) [35] and GSE72280 (metastatic melanoma cohort) were studied [36].